Here is the design of a clinical trial:

Official Title: Impact of Atorvastatin on Prostate Cancer Progression After Initiation of Androgen Deprivation Therapy - Lipid Metabolism as a Novel Biomarker to Predict Prostate Cancer Progression

Included conditions:
- Metastatic Prostate Cancer
- Recurrent Prostate Cancer

Study Armgroups:
- {'label': 'Atorvastatin', 'type': 'EXPERIMENTAL', 'description': 'Capsules of atorvastatin. Daily dose of 80 mg for max. 10 years or until development of castration resistance.', 'interventionNames': ['Drug: Atorvastatin 80mg']}
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Identical capsules as in the atorvastatin arm, but including no active ingredient. Used daily for max. 10 years or until development of castration resistance', 'interventionNames': ['Drug: Placebo oral capsule']}

Interventions:
- {'type': 'DRUG', 'name': 'Atorvastatin 80mg', 'description': 'Capsules including 80 mg of atorvastatin', 'armGroupLabels': ['Atorvastatin'], 'otherNames': ['Lipitor']}
- {'type': 'DRUG', 'name': 'Placebo oral capsule', 'description': 'Similar capsules as in the atorvastatin arm, but without the active ingredient', 'armGroupLabels': ['Placebo']}

Primary Outcomes:
- {'measure': 'Castration resistance', 'description': 'Castration resistance is defined as PSA progression (three consecutive PSA rises measured at least 1 week apart with two \\> 50% increases over the nadir and PSA \\> 2 ng/ml) or radiological disease progression (appearance of two or more lesions in bone scan or soft tissue enlargement as per RECIST criteria) with serum testosterone at castrate level (\\< 1.73 nmol/l; 50 ng/dl) during ADT.', 'timeFrame': 'From date of randomization until the date of first occurrence of castration resistance, assessed up to 60 months'}

Please estimate the sample size based on the assumption: 
Alpha 0.05, beta 0.20 (power 0.80), 10% dropout rate, interim analysis after 100 participants, post hoc follow-up, maximum intervention duration of 10 years.
Sample size calculation
        In a cohort study by Harshman et al,23 among men starting ADT, 58% of the statin users and 75% of non-users of statins progress to castration resistance during median 5.8 years. We used these crude percentages for sample size calculations.
        With alpha and beta values of 0.05 and 0.20 (power=0.80), sample size of 400 men will be enough to detect a risk difference with HR 0.65 (figure 2). We assume 10% drop-out rate in each study arm. The programme âPSâPower and sample size, V.3.1.2â was used for the calculation.
        
          Figure 2
          
            Sample size estimation with power 0.8 as a function of HR. Calculation was made based on study by Harshman et al.23
          
          
        
        The median time to disease progression is assumed to be 12â15 months for patients with de novo metastatic disease and 33 months for patients recurring after primary therapy.3â7 Therefore, the intervention will continue until castration resistance, death, or for maximum of 10 years. Post hoc follow-up will continue after the intervention. A 3 monthsâ difference in time to castration resistance between the study arms will be considered clinically significant.
        It has to be noted that the number of studies published on this topic is low and, in the absence of randomised evidence on this topic, the power calculation is based on results of epidemiological study prone to residual bias. Therefore, an interim analysis will be performed after the first 100 participants have met the primary endpoint, that is, progressed into castration resistance. Without lifting the blinding, the power calculations are repeated to verify whether the chosen sample size has adequate statistical power to detect statistically significant difference of the effect size observed between the randomisation groups at that time. If the calculations suggest that a larger sample size is needed for the trial, the study protocol will be amended with updated recruitment target.